Print

HPTN 084

NCT03164564

Trial Details:

III Ongoing
Cabotegravir
RandD/trials/Lists/ClinicalTrialsList
5/1/2022
?daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will